Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy,…Details
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application and resulting in FDA approval to conduct a First Stage…Details
“I don’t mean to disappoint,” said William Maisel, chief medical officer at FDA’s Center for Devices and Radiological Health (CDRH). The agency’s proposed plans to blend together certain provisions of 21 CFR Part 820 with ISO 13485 through new rulemaking have been public for about a year “so it’s not new, but it’s true that we…Details
“Stated simply, we formulate the goop, we buy all the raw materials to mix the goop” ….. Fine, here’s your warning letter.
Every ‘small company’ likes to proclaim it’s uniqueness and the astute one’s do it simply – providing a direct yet compelling message on their website. One such company in the SE USA includes an interview with their SVP, Contract Sales: Human & Animal Health: [#1] Q: What do you do? A: We manufacture over-the-counter drug products,…Details
By: RinaWolf I recently had the opportunity to speak with an international company about what it takes to bring a new diagnostic test to market in the United States. During the course of our discussion, I began to reflect on just how tricky, time-consuming, and expensive if can be to bring a new test to…Details
We are grateful to have a growing talented team.
Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals. Company Selects TAMM Net as FDA Consultant to Lead Regulatory Actions for USF Treatment SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its…Details
Award recognizes company’s contribution to Florida’s life sciences industry ALACHUA, Fla., Oct. 18, 2017 (GLOBE NEWSWIRE) — AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Year Award. The award, presented this week at the 20th anniversary…Details